References

  1. Imbart-comte L, Demoly P. Les accoutumances médicamenteuses. Revue française d'allergologie et d'immunologie clinique. 2004 ; 44(3): 308-314. PubMed | Google Scholar

  2. Pur ozyigit LP, Galerac ,Defrance C, Kilicaslan Z , Demoly P. Allergie aux antituberculeux, une solution thérapeutique pragmatique : la désensibilisation au rifater. Revue française d'allergologie. 2011 ; 51(4) : 446-448. PubMed | Google Scholar

  3. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol. 2000 june; 105(6Pt2): s634-7. PubMed | Google Scholar

  4. Fenniche S, Maalej S, Fekih L, Hassene H, Belhabib D, Megdiche ML. Manifestations d'hypersensibilité à la rifampicine. Presse Med. 2003 Jule; 32(25): 1167-9. PubMed | Google Scholar

  5. Portales-casamar s, Demoly p. Cdrom encyclopédique d'allergologie. Resip. Edition 200. PubMed | Google Scholar

  6. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003; 139(8): 683-93. PubMed | Google Scholar

  7. Goldin HM, Schweitzer WJ, Bronson DM. Rifampicin and exfoliative dermatitis. Ann Intern Med. 1987; 107(5): 789. PubMed | Google Scholar

  8. Roujeau JC. Toxic epidermal necrolysis and stevens-johnson syndrome. Rev Prat. 2007; 57(11): 1165-70. PubMed | Google Scholar

  9. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994; 331(19): 1272-85. PubMed | Google Scholar

  10. Drira I, Souissi R, Dakhlaoui R, Jeguirim MS, Chebbi ML. Désensibilisation orale aux antituberculeux. Rev Pneumol Clin. 1997; 53(2): 104-6. PubMed | Google Scholar

  11. Matz T, Borish LC, Routes JM, Rosenwasser LJ. Oral desensitization to rifampicin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med. 1994; 149 (3 Pt 1): 815-7. PubMed | Google Scholar

  12. Leophonte p, Didier a, carre p, Pouchelon e, Rouquet rm. Modalites thérapeutiques de la tuberculose pulmonaire. Rev Prat. 1990; 40(8): 719-4. PubMed | Google Scholar

  13. Denis J, Robert A, Johanet C, Homberg JC, Opolon P, Levy VG. Accident immunoallergique à la rifampicine avec coagulation intravasculaire disséminée. Presse Med. 1983; 12(23): 1479-81. PubMed | Google Scholar

  14. Lee CH, Lee CJ. Thrombocytopenia: a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest. 1989; 96(1): 202-3. PubMed | Google Scholar

  15. Shishido Y, Nagayama N, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S. Agranulocytosis due to anti-tuberculosis drugs including isoniazid (inh) and rifampicin (rfp) - a case report of four cases and review of the literature. Kekkaku. 2003; 78(11): 683-9. PubMed | Google Scholar

  16. Nagayama N, Shishido Y, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S. Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid. Kekkaku. 2004; 79(5): 341-8. PubMed | Google Scholar

  17. Demoly P, Hillaire-buys D, Raison-peyron N, et al. Comprendre les allergies médicamenteuses. Médecine/Sciences. 2003; 19(3):327-36. PubMed | Google Scholar